Jardiance (Empagliflozin) is Safe and Recommended for This Patient
For a patient with atherosclerosis, coronary artery stent, solitary kidney, and CKD stage 2, empagliflozin (Jardiance) is not only safe but strongly recommended. This patient profile represents exactly the population that derives the greatest cardiovascular and renal protection from SGLT2 inhibitors.
Why This Patient Should Take Jardiance
Cardiovascular Benefits in Atherosclerotic Disease
This patient has established atherosclerotic cardiovascular disease (ASCVD) with a coronary stent. The most recent 2025 ADA guidelines explicitly recommend SGLT2 inhibitors for patients with established ASCVD, independent of diabetes status or A1C levels 1. The EMPA-REG OUTCOME trial demonstrated that empagliflozin reduces cardiovascular death by 38% and hospitalization for heart failure by 35% in patients with established cardiovascular disease 2.
Kidney Protection with Solitary Kidney
Having only one kidney makes renal protection paramount. The 2022 KDIGO/ADA consensus and 2025 ADA guidelines recommend initiating SGLT2 inhibitors for patients with CKD stage 2 (eGFR 60-89 mL/min/1.73 m²) to slow CKD progression 3. With CKD stage 2, this patient's eGFR is well above the minimum threshold of 20 mL/min/1.73 m² for empagliflozin initiation 3.
The EMPA-KIDNEY trial specifically demonstrated that empagliflozin:
- Reduces progression of kidney disease or cardiovascular death by 28% (HR 0.72) 4
- Slows eGFR decline by 1-2 mL/min/1.73 m²/year 5
- Reduces risk of kidney failure by 53% in patients with CKD 5
These benefits were consistent across all eGFR ranges studied, including patients with eGFR as low as 20 mL/min/1.73 m² 3, 4.
Safety Profile for This Specific Patient
No Contraindications Present
According to FDA labeling, empagliflozin has no contraindications related to:
- Atherosclerosis or coronary stents
- Solitary kidney status
- CKD stage 2 6
The only absolute contraindications are hypersensitivity to empagliflozin, severe renal impairment (eGFR <20 mL/min/1.73 m²), end-stage renal disease, or dialysis 6.
Proven Safety in CKD
A pooled analysis of 15,081 patients demonstrated that empagliflozin is safe in patients with moderate to severe CKD (stages G3-4), with:
- Similar rates of serious adverse events compared to placebo
- Lower risk of hyperkalemia (HR 0.59) 7
- Lower risk of edema (HR 0.47) 7
- No increased risk of acute kidney injury 7
The 2024 meta-analysis of 29,614 patients confirmed empagliflozin's safety profile with no increased risk of serious adverse events, bone fractures, or amputations 8.
Practical Monitoring and Risk Mitigation
Initial Assessment
Before starting, verify:
- Current eGFR (should be >20 mL/min/1.73 m²)
- Volume status (especially if on diuretics)
- Not acutely ill or dehydrated
Dose Selection
Start empagliflozin 10 mg once daily 9, 6. No dose adjustment is needed for CKD stage 2 9.
Expected Initial Changes
- Expect a transient eGFR decline of 3-5 mL/min/1.73 m² within the first 4 weeks 3. This is hemodynamic, reversible, and does not require discontinuation.
- Continue therapy even if eGFR temporarily dips, as long-term kidney protection is maintained 3.
Monitoring Schedule
- Week 1-4: Check eGFR, electrolytes, volume status
- Month 3: Reassess eGFR, blood pressure
- Ongoing: Monitor every 3-6 months
Managing Potential Adverse Events
Volume depletion (most relevant with solitary kidney):
- Monitor for orthostatic hypotension, dizziness
- Consider reducing diuretic dose if patient is on one 3
- Ensure adequate hydration
- Hold during acute illness 3
Genital mycotic infections (6% incidence):
- Counsel on hygiene
- Treat with topical antifungals if occurs
- Rarely requires discontinuation 6
Urinary tract infections (9.3% vs 7.6% placebo):
- Monitor for symptoms
- Treat promptly with antibiotics 6
Ketoacidosis (rare, <0.1%):
- Only relevant if patient has diabetes and uses insulin
- Maintain at least low-dose insulin if applicable
- Hold during acute illness 3
Common Pitfalls to Avoid
Don't stop empagliflozin if eGFR drops initially - This is expected and protective long-term 3
Don't withhold due to "only one kidney" concern - The solitary kidney makes renal protection MORE important, not less. EMPA-KIDNEY showed consistent benefits regardless of baseline kidney function 4
Don't wait for diabetes diagnosis - Cardiovascular and renal benefits occur independent of glucose-lowering effects 10, 11
Don't discontinue during minor illnesses - Only hold during severe illness with dehydration or inability to maintain oral intake 3
Bottom Line
This patient should start empagliflozin 10 mg daily immediately. The combination of atherosclerotic disease with coronary stent and CKD stage 2 with solitary kidney represents a strong indication for SGLT2 inhibitor therapy based on the highest quality evidence from multiple large randomized trials 10, 3, 4. The safety profile is well-established, and the cardiovascular and renal protective benefits far outweigh minimal risks in this patient population 8, 7.